[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3534 followers Created: 2025-07-11 18:15:25 UTC William Blair, on 7/7, reiterated $LENZ at an Outperform rating and said, "We see a potential blockbuster opportunity for LNZ100," after Lenz announced an exclusive license and commercialization agreement with Laboratoires Théa for LNZ100 in Canada." $ABBV William Blair additionally said, "Lenz is eligible to receive over $XX million in milestones ($7.5 million in upfront and regulatory milestones and $XX million in commercial milestones), as well as tiered double-digit royalties on net sales. Overall, we view this as a good deal for Lenz, as the company retains good economics without having to build out commercial infrastructure in the Canadian market. While the first pharmacologic therapy for presbyopia, Vuity, failed to gain traction in the community due to limited efficacy and a short duration of effect, Lenz's Phase II INSIGHT study and Phase III CLARITY studies of LNZ100 (aceclidine 1.75%) showed impressive efficacy, with response rates of 71%-73% within a half hour of dosing and daylong durability. We believe the early enthusiasm for Vuity demonstrates the significant appetite for a product that offers durable efficacy such as that shown with LNZ100 in Phase Il and III trials. We see a potential blockbuster opportunity for LNZ100." XXXXX engagements  **Related Topics** [canada](/topic/canada) [$lenz](/topic/$lenz) [$abbv](/topic/$abbv) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/Quantumup1/status/1943735897062871123)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3534 followers
Created: 2025-07-11 18:15:25 UTC
William Blair, on 7/7, reiterated $LENZ at an Outperform rating and said, "We see a potential blockbuster opportunity for LNZ100," after Lenz announced an exclusive license and commercialization agreement with Laboratoires Théa for LNZ100 in Canada." $ABBV William Blair additionally said, "Lenz is eligible to receive over $XX million in milestones ($7.5 million in upfront and regulatory milestones and $XX million in commercial milestones), as well as tiered double-digit royalties on net sales.
Overall, we view this as a good deal for Lenz, as the company retains good economics without having to build out commercial infrastructure in the Canadian market.
While the first pharmacologic therapy for presbyopia, Vuity, failed to gain traction in the community due to limited efficacy and a short duration of effect, Lenz's Phase II INSIGHT study and Phase III CLARITY studies of LNZ100 (aceclidine 1.75%) showed impressive efficacy, with response rates of 71%-73% within a half hour of dosing and daylong durability. We believe the early enthusiasm for Vuity demonstrates the significant appetite for a product that offers durable efficacy such as that shown with LNZ100 in Phase Il and III trials.
We see a potential blockbuster opportunity for LNZ100."
XXXXX engagements
Related Topics canada $lenz $abbv stocks healthcare